FOLD Q3 2025 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$169M+19.5% YoY

Gross Profit

$148M87.4% margin

Operating Income

$34M20.3% margin

Net Income

$17M10.2% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+9.3%

Cash Flow

Operating Cash Flow

$36M

Free Cash Flow

$35M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$869M

Total Liabilities

$638M

Stockholders' Equity

$230M

Cash & Equivalents

$191M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$169M	$142M	+19.5%
Gross Profit	$148M	$128M	+15.2%
Operating Income	$34M	$22M	+58.2%
Net Income	$17M	-$7M	+357.2%

Geographic Segments

Non-US

$81M59%

UNITED STATES

$57M41%